يعرض 1 - 10 نتائج من 123 نتيجة بحث عن '"Ma, Y. T."', وقت الاستعلام: 0.94s تنقيح النتائج
  1. 1
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: https://edoc.unibas.ch/93559/1/20230210104934_63e6132ec2371.pdfTest; Ghaneh, P. and Palmer, D. and Cicconi, S. and Jackson, R. and Halloran, C. M. and Rawcliffe, C. and Sripadam, R. and Mukherjee, S. and Soonawalla, Z. and Wadsley, J. and Al-Mukhtar, A. and Dickson, E. and Graham, J. and Jiao, L. and Wasan, H. S. and Tait, I. S. and Prachalias, A. and Ross, P. and Valle, J. W. and O'Reilly, D. A. and Al-Sarireh, B. and Gwynne, S. and Ahmed, I. and Connolly, K. and Yim, K. L. and Cunningham, D. and Armstrong, T. and Archer, C. and Roberts, K. and Ma, Y. T. and Springfeld, C. and Tjaden, C. and Hackert, T. and Büchler, M. W. and Neoptolemos, J. P. and European Study Group for Pancreatic Cancer, . (2023) Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol, 8 (2). pp. 157-168.; info:pmid/36521500; urn:ISSN:2468-1253 (Electronic)

  2. 2
    دورية أكاديمية
  3. 3
  4. 4
    مؤتمر

    المساهمون: University of Manchester/The Christie NHS Foundation Trust, Manchester

    العلاقة: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS4183Test; McNamara MG, Timmins H, Osborne A, Cox R, Wasan HS, Corrie P, et al. ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/ gem). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005635.; http://hdl.handle.net/10541/626670Test; Journal of Clinical Oncology

  5. 5
    دورية أكاديمية

    المساهمون: M. Kalisvaart, D. Broadhurst, F. Marcon, R. Pande, A. Schlegel, R. Sutcliffe, R. Marudanayagam, D. Mirza, N. Chatzizacharia, M. Abradelo, P. Muiesan, J. Isaac, Y.T. Ma, C. McConville, K. Roberts

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32046922; info:eu-repo/semantics/altIdentifier/wos/WOS:000576755500002; volume:22; issue:9; firstpage:1240; lastpage:1249; numberofpages:10; journal:HPB; http://hdl.handle.net/2434/883179Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85079066108

  6. 6
    دورية أكاديمية

    المصدر: Corrie , P G , Qian , W , Basu , B , Valle , J , Falk , S , Iwuji , C , Wasan , H , Palmer , D , Scott-Brown , M , Wadsley , J , Arif , S , Bridgewater , J , Propper , D , Gillmore , R , Gopinathan , A , Skells , R , Bundi , P , Brais , R , Dalchau , K , Bax , L , Chhabra , A , Machin , A , Dayim , A , McAdam , K , Cummins , ....

  7. 7
  8. 8
    دورية
  9. 9
    دورية أكاديمية

    المساهمون: The Christie NHS Foundation Trust, Manchester, UK.

    العلاقة: https://dx.doi.org/10.1016/j.xcrm.2023.101307Test; Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, et al. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial. Cell reports Medicine. 2023 Dec 19;4(12):101307. PubMed PMID: 38056464. Pubmed Central PMCID: PMC10772343. Epub 2023/12/07. eng.; http://hdl.handle.net/10541/626826Test; Cell Reports. Medicine.

  10. 10